Stock Events

Stock Events

Ocugen 

€0.8190
814
+€0.09+12.97%Friday 16:30

Statistics

Day High
0.736
Day Low
0.729
52W High
0.83
52W Low
0.635
Volume
-
Avg. Volume
-
Mkt Cap
277.73M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 4Expected
Q2 2026
Q3 2026
-0.06
-0.04
-0.03
-0.01
Expected EPS
-0.053404799999999995
Actual EPS
-0.0089008

Financials

-1,524.28%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
3.86MRevenue
-58.87MNet Income

Analyst Ratings

$7.78Average Price Target
The highest estimate is ⁦8.35⁩.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2H51.XETRA. It's not an investment recommendation.
Apple
105
AAPL
Amazon
94
AMZN
Tesla
90
TSLA
NVIDIA
88
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap88.52B
Moderna is a competitor because it focuses on mRNA technology for vaccines, including COVID-19, similar to Ocugen's focus on developing a COVID-19 vaccine.
BioNTech
BNTX
Mkt Cap22.15B
BioNTech competes directly with Ocugen in the COVID-19 vaccine space, having developed one of the first mRNA vaccines for the virus.
Novavax
NVAX
Mkt Cap1.66B
Novavax is a competitor due to its work on developing protein-based vaccines for COVID-19, offering an alternative to Ocugen's vaccine approach.
Pfizer
PFE
Mkt Cap173.95B
Pfizer is a major player in the COVID-19 vaccine market, competing with Ocugen through its collaboration with BioNTech to develop an mRNA vaccine.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson competes with Ocugen by offering a viral vector COVID-19 vaccine, providing a different technology approach in the same market.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca is in competition with Ocugen due to its viral vector vaccine for COVID-19, which is a direct alternative to Ocugen's vaccine development efforts.
Inovio Pharmaceuticals
INO
Mkt Cap62.29M
Inovio Pharmaceuticals is a competitor because it is developing DNA-based vaccines for COVID-19, positioning it as an alternative to Ocugen's vaccine technology.
Arbutus Biopharma
ABUS
Mkt Cap834.03M
Arbutus Biopharma competes with Ocugen in the broader field of biopharmaceuticals, focusing on viral diseases and vaccine technologies.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline is a competitor because it is involved in the development and distribution of vaccines, including efforts towards COVID-19, competing in the same market as Ocugen.

About

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Show More
CEO
Shankar Musunuri
Employees
116
Country
United States
ISIN
US67577C1053
WKN
000A2PSZH

Listings

F
DE
2H51.F
STU
DE
2H51.STU
MU
DE
2H51.MU
BOATS
BOATS
OCGN.BOATS

0 Comments

Share your thoughts

FAQs

What is Ocugen stock price today?▼
The current price of 2H51.XETRA is €0.82 EUR — it has increased by +12.97% in the past 24 hours. Watch Ocugen stock price performance more closely on the chart.
What is Ocugen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Ocugen stocks are traded under the ticker 2H51.XETRA.
What is Ocugen market cap?▼
Today Ocugen has the market capitalization of 277.73M
When is the next Ocugen earnings date?▼
Ocugen is going to release the next earnings report on March 10, 2027.
What were Ocugen earnings last quarter?▼
2H51.XETRA earnings for the last quarter are -0.01 EUR per share, whereas the estimation was -0.05 EUR resulting in a +83.33% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Ocugen revenue for the last year?▼
Ocugen revenue for the last year amounts to 3.86M EUR.
What is Ocugen net income for the last year?▼
2H51.XETRA net income for the last year is -58.87M EUR.
How many employees does Ocugen have?▼
As of November 8, 2026, the company has 116 employees.
In which sector is Ocugen located?▼
Ocugen operates in the Health & Wellness sector.
When did Ocugen complete a stock split?▼
Ocugen has not had any recent stock splits.
Where is Ocugen headquartered?▼
Ocugen is headquartered in MALVERN, United States.